The child was in decompensated
septic shock with respiratory failure and multi-organ dysfunction.
Intercept Pharmaceuticals announced that the Ocaliva, obeticholic acid or OCA, Prescribing Information in the United States has been updated to reinforce appropriate dosing in primary biliary cholangitis, or PBC, patients with Child-Pugh Class B or C or decompensated
These positive secondary findings came from a study of 66 patients at least 55-years old who had been discharged from hospitalization for acute decompensated
Patients were categorized into Treatment naive, treatment experienced and decompensated
chronic liver disease.
Renova Therapeutics plans to advance development of the stresscopin program as RT-400, a peptide infusion treatment for episodes of Acute Decompensated
Objective: To compare the serum sodium levels in compensated (Child Pugh A) and decompensated
cirrhosis (Child Pugh C) secondary to chronic viral hepatitis C.
In ASTRAL-4, patients with decompensated
cirrhosis receiving Epclusa with RBV for 12 weeks achieved a high SVR12 rate (94%) compared to those who received Epclusa for 12 weeks or 24 weeks (83% and 86%, respectively).
Bristol-Myers Squibb Canada announced Health Canada's approval of Daklinza (daclatasvir), in combination with sofosbuvir (with or without ribavirin) for 12 weeks in the treatment of chronic hepatitis C (CHC) in adult patients with hepatitis C vims (HCV) genotypes 1,2 or 3 in three difficult-to-treat populations, including patients with HIV-1 co-infection, patients with compensated or decompensated
cirrhosis and patients with HCV recurrence after liver transplantation.
J-ty was diagnosed with decompensated
liver disease secondary to neonatal hepatitis at the Philippine General Hospital on May 18, 2015, just over four months after he was born.
The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl's lead asset CXL-1427, a novel nitroxyl donor (prodrug) in Phase 2 clinical development as an intravenous treatment for acute decompensated
ORLANDO--Three simple, routinely collected measurements together provide a lot of insight into the risk faced by community-dwelling patients hospitalized for acute decompensated
heart failure, according to data collected from 3,628 patients at one U.
based Cardioxyl's lead asset CXL-1427, a novel nitroxyl drug that has entered Phase II clinical development as an intravenous treatment for acute decompensated